Old and new oral anticoagulants in management of atrial fibrillation: A double-edged sword for women

Current Vascular Pharmacology

Volumn 13, Issue 6, 2015, Pages 738-748

  Basili, Stefania ^a   Raparelli, Valeria ^a   Proietti, Marco ^a   Napoleone, Laura ^a   Ferroni, Patrizia ^b   Franconi, Flavia ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Faculty of Architecture and Industrial Design   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

Anticoagulant therapy; Atrial fibrillation; Gender differences; New oral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BETRIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; PROTHROMBIN COMPLEX; RIVAROXABAN; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

ACUTE HEART INFARCTION; ANKLE BRACHIAL INDEX; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DECISION MAKING; FEMALE; HEART INFARCTION; HUMAN; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; SEX DIFFERENCE; THROMBOSIS; ADULT; CHEMICALLY INDUCED; COMPLICATION; ORAL DRUG ADMINISTRATION; STROKE; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; MALE; RISK FACTORS; SEX FACTORS; STROKE; THROMBOEMBOLISM;

EID: 84945911568     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161113666150216152054     Document Type: Article

References (91)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285(18): 2370-5.
2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114(2): 119-25.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98(10): 946-52.
4. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community- based study. J Am Coll Cardiol 2007; 49(9): 986-92.
5. Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 2011; 305(20): 2080-7.
6. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrilla tion: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112(12): 1687-91.
7. Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012; 307(18): 1952-8.
8. Meschia JF, Merrill P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke 2010; 41(4): 581-7.
9. Michelena HI, Powell BD, Brady PA, et al. Gender in atrial fibrillation: Ten years later. Gend Med 2010; 7(3): 206-17.
10. Rantanen K, Tatlisumak T. Stroke in women - oral contraception, pregnancy, and hormone replacement therapy. Curr Vasc Pharmacol 2013; 11(1): 58-73.
11. Polimeni L, Perri L, Saliola M, et al. The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. Intern Emerg Med 2010; 5(2): 91-4.
12. Violi F, Davi G, Hiatt W, et al. Prevalence of Peripheral Artery Disease by Abnormal Ankle-Brachial Index in Atrial Fibrillation: Implications for Risk and Therapy. J Am Coll Cardiol 2013; 62(23): 2255-6.
13. Soliman EZ, Safford MM, Muntner P, et al. Atrial Fibrillation and the Risk of Myocardial Infarction. JAMA Intern Med 2014; 174(1): 107-14.
14. Perlstein TS, Creager MA. The ankle-brachial index as a biomarker of cardiovascular risk: it's not just about the legs. Circulation 2009; 120(21): 2033-5.
15. Lauffenburger JC, Robinson JG, Oramasionwu C, et al. Racial/ ethnic and gender gaps in the use and adherence of evidencebased preventive therapies among elderly medicare part D beneficiaries after acute myocardial infarction. Circulation 2014; 129(7): 754-63.
16. Marijon E, Le Heuzey JY, Connolly S, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013; 128(20): 2192-201.
17. American College of Cardiology Foundation; American Heart Association; European Society of Cardiology; et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013; 127(18): 1916-26.
18. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 2012; 141(2): e531S-75S.
19. Lip GY, Laroche C, Boriani G, et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace 2015; 17(1): 24-31.
20. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167(13): 1414-9.
21. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e44S-88S.
22. Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med 2011; 12(4): 386-92.
23. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102(2): 268-78.
24. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008; 39(6): 1901-10.
25. Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51(8): 816-7.
26. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart survey on atrial fibrillation. Chest 2010; 137(2): 263-72.
27. Mason PK, Lake DE, Di Marco JP, et al. Impact of the CHA2DS2- VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med 2012; 125(6): 603.e1-6.
28. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093-100.
29. Mauer AC, Khazanov NA, Levenkova N, et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011; 9(1): 100-8.
30. Apostolakis S, Lane DA, Buller H, et al. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thromb Haemost 2013; 110(5): 1074-9.
31. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003; 15(3): 213-6.
32. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167(3): 239-45.
33. Rose AJ, Hylek EM, Ozonoff A, et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8(10): 2182-91.
34. Nilsson H, Grove EL, Larsen TB, et al. Sex differences in treatment quality of self-managed oral anticoagulant therapy: 6,900 patient- years of follow-up. PLoS One 2014; 9(11): e113627.
35. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin: The SAMe-TT2R2 Score. Chest 2013; 144(5): 1555-63.
36. Lip GY, Lane DA, Buller H, et al. Development of a Novel Composite Stroke and Bleeding Risk Score in Patients With Atrial Fibrillation: The AMADEUS Study. Chest 2013; 144(6): 1839-47.
37. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12): 857-67.
38. Di Raimondo D, Tuttolomondo A, Buttà C, et al. Antivitamin K drugs in stroke prevention. Curr Vasc Pharmacol 2013; 11(6): 817- 23.
39. Foley J, Kirchhof P, Lip GY. Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all? Curr Vasc Pharmacol 2014; 12(3): 373-83.
40. Di Minno MN, Russolillo A, Camera M, et al. New anti-thrombotic drugs for stroke prevention. Curr Vasc Pharmacol 2011; 9(6): 723- 32.
41. Connolly SJ, Eikelboom J, O'Donnell M, et al. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation 2007; 116(4): 449-55.
42. Van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129(5): 1155-66.
43. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin associated intracranial and extracranial hemorrhages. Am J Med 2007; 120(8): 700-5.
44. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.
45. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.
46. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
47. Marietta M, Pedrazzi P, Girardis M, et al. Intracerebral haemorrhage: an often neglected medical emergency. Intern Emerg Med 2007; 2(1): 38-45.
48. Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43(7): 1812-7.
49. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363(19): 1875-6.
50. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of longterm anticoagulant therapy (RE-LY) trial. Circulation 2011; 123(21): 2363-72.
51. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-104.
52. Adam SS, Mc Duffie JR, Ortel TL, et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012; 157(11): 796-807.
53. Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a metaanalysis of 50,578 patients. Int J Cardiol 2013; 167(4): 1237-41.
54. Schulman S, Kearon C, the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3(4): 692-4.
55. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383(9921): 955-62.
56. Pancholy SB, Sharma PS, Pancholy DS, et al. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014; 113(3): 485-90.
57. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118(7): 511-20.
58. Humphries KH, Kerr CR, Connolly SJ, et al. New onset atrial fibrillation: Sex differences in presentation, treatment, and outcome. Circulation 2001; 103(19): 2365-70.
59. Gomberg-Maitland M, Wenger NK, Feyzi J, et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 2006; 27(16): 1947-53.
60. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84(2): 527-39.
61. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343(8899): 687-91.
62. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348(9028): 633-8.
63. Alotaibi GS, Almodaimegh H, McMurtry MS, et al. Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis. Thromb Res 2013; 132(2): 185-9.
64. Goodman SG, Wojdyla DM, Piccini JP, et al. Factors Associated with Major Bleeding Events: Insights from the Rivaroxaban Oncedaily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) J Am Coll Cardiol 2014; 63(9): 891- 900.
65. Takach Lapner S, Cohen N, Kearon C. Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and metaanalysis. J Thromb Haemost 2014; 12(5): 595-605.
66. Wang TY, Angiolillo DJ, Cushman M, et al. Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol 2012; 59(10): 891-900.
67. Whitley H, Lindsey W. Sex-based differences in drug activity. Am Fam Physician 2009; 80(11): 1254-8.
68. Jabbour HN, Sales KJ, Catalano RD, et al. Inflammatory pathways in female reproductive health and disease. Reproduction 2009; 138(6): 903-19.
69. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009; 53(3): 221-31.
70. Tarantino MD, Kunicki TJ, Nugent DJ. The estrogen receptor is present in human megakaryocytes. Ann N Y Acad Sci 1994; 714: 293-6.
71. Khetawat G, Faraday N, Nealen ML, et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95(7): 2289-96.
72. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006; 295(12): 1420-7.
73. Basili S, Raparelli V, Proietti M, et al. Impact of Sex and Gender on the Efficacy of Antiplatelet Therapy: The Female Perspective. J Atheroscler Thromb 2015; 22(2): 109-25.
74. Haque SF, Matsubayashi H, Izumi S, et al. Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J 2001; 48(1): 33-41.
75. Gurbel PA, Bliden KP, Cohen E, et al. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis 2008; 19(4): 268-75.
76. Hobson AR, Qureshi Z, Banks P, et al. Gender and responses to aspirin and clopidogrel: insights using short thrombelastography. Cardiovasc Ther 2009; 27 (4): 246-52.
77. Lev EI, Bliden KP, Jeong YH, et al. Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. J Am Heart Assoc 2014; 3(5): e001167.
78. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114(5-6): 409-14.
79. Lichtman JH, Wang Y, Jones SB, et al. Age and sex differences in inhospital complication rates and mortality after percutaneous coronary intervention procedures: evidence from the NCDR(®). Am Heart J 2014; 167(3): 376-83.
80. Hess CN, McCoy LA, Duggirala HJ, et al. Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from TRANSLATE-ACS. J Am Heart Assoc 2014; 3(1): e000523.
81. Knol HM, Kemperman RF, Kluin-Nelemans HC, et al. Haemostatic variables during normal menstrual cycle. A systematic review. Thromb Haemost 2012; 107(1): 22-9.
82. Cleuren AC, Van der Linden IK, De Visser YP, et al. 17α- Ethinylestradiol rapidly alters transcript levels of murine coagulation genes via estrogen receptor α. J Thromb Haemost 2010; 8(8): 1838-46.
83. Farsetti A, Misiti S, Citarella F, et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 1995; 136(11): 5076-83.
84. Siegerink B, Govers-Riemslag JW, Rosendaal FR, et al. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation 2010; 122(18): 1854-61.
85. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91(7): 1952- 8.
86. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340(23): 1801-11.
87. Bonithon-Kopp C, Scarabin PY, Bara L, et al. Relationship between sex hormones and haemostatic factors in healthy middleaged men. Atherosclerosis 1988; 71(1): 71-6.
88. Violi F, Calvieri C, Ferro D, et al. Statins as antithrombotic drugs. Circulation 2013; 127(2): 251-7.
89. Kostapanos MS, Liberopoulos EN, Goudevenos JA, et al. Do statins have an antiarrhythmic activity? Cardiovasc Res 2007; 75(1): 10-20.
90. Banach M, Mikhailidis DP, Kjeldsen SE, et al. Time for new indications for statins? Med Sci Monit 2009; 15(12): MS1-5.
91. Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45(5): 1545-88.